Article

Synchronous rectal and hepatic resection of rectal metastatic disease.

Division of Gastroenterologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Journal of Gastrointestinal Surgery (Impact Factor: 2.36). 09/2011; 15(9):1583-8. DOI: 10.1007/s11605-011-1604-9
Source: PubMed

ABSTRACT The objectives were to determine the feasibility of combined rectal and hepatic resections and analyze the disease-free survival and overall survival.
Sixty patients who underwent resection for metastatic rectal disease from 1991 to 2005 at Mayo Clinic were reviewed. Inclusion criteria were: rectal cancer with metastatic liver disease and resectability of metastases. The exclusion criteria were: metachronous resection (n = 15). Kaplan-Meier Survival estimated overall survival (OS) and disease-free survival (DFS). Cox proportional hazard models examined the association between groups and survival.
The cohort comprised 22 men and 23 women, with median age of 63 years. Surgical management included: abdominoperineal resection, 13 patients (29%); low anterior resection, 29 (64%); local excision, one; total proctocolectomy, one; and pelvic exenteration, one. Major hepatic resection was performed in 22%. There was no mortality, but there were 26 postoperative complications. Disease-free survival from local recurrence at 1, 2, and 5 years was 92%, 86%, and 80%, respectively. Disease-free survival from distant recurrence at 1, 2, and 5 years was 62%, 43%, and 28%, respectively. Overall survival at 1, 2 and 5 years was 88%, 72%, and 32%, respectively.
Combined rectal and hepatic resection is safe. Morbidity and mortality do not preclude concurrent resection. The DFS and OS are comparable to that of patients undergoing a staged procedure.

1 Bookmark
 · 
104 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Up to a quarter of patients with rectal cancer have synchronous liver metastases at the time of diagnosis. This is a predictor of poor outcome. There are no standardized guidelines for treatment. We reviewed the outcomes of our patients with synchronous rectal liver metastases treated with a curative intent by neo-adjuvant chemotherapy with or without chemoradiotherapy followed by resection of primary tumor and then liver metastases. Between 2004 and 2012, patients who presented with rectal cancer and synchronous liver metastasis were treated with curative intent with perioperative systemic chemotherapy as the 1(st) line of treatment. Responders to chemotherapy underwent resection of the primary tumor with or without preoperative chemoradiotherapy (CRT) followed by hepatic resection. Fifty-three rectal cancer patients with 152 synchronous liver lesions were identified. After a median follow-up of 29.6 months, the median survival was 41.4 months. Overall survival (OS) was 59.0% at 3 years and 39.0% at 5 years. Rectal resection before hepatic resection, combined with neoadjuvant chemotherapy is associated with promising clinical outcome. It allows down-staging of liver lesions and removal of the primary tumor before the progression of further micrometastases. Furthermore, patients that do not respond to chemotherapy can be identified and may avoid major surgical intervention. This article is protected by copyright. All rights reserved.
    Colorectal Disease 12/2013; · 2.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The optimal management of colorectal cancer with synchronous liver metastases has not yet been elucidated. The aim of the present study was systematically to review current evidence concerning the timing and sequence of surgical interventions: colon first, liver first or simultaneous.MethodsA systematic literature review was performed of clinical studies comparing the timing and sequence of surgical interventions in patients with synchronous liver metastases. Retrospective studies were included but case reports and small case series were excluded. Preoperative and intraoperative data, length of hospital stay, perioperative mortality and morbidity, and 1-, 3- and 5-year survival rates were compared. The studies were evaluated according to a modification of the methodological index for non-randomized studies (MINORS) criteria.ResultsEighteen papers were included and 21 entries analysed. Five entries favoured the simultaneous approach regarding duration of procedure, whereas three showed no difference; five entries favoured simultaneous treatment in terms of blood loss, whereas in four there was no difference; and all studies comparing length of hospital stay favoured the simultaneous approach. Five studies favoured the simultaneous approach in terms of morbidity and eight found no difference, and no study demonstrated a difference in perioperative mortality. One study suggested a better 5-year survival rate after staged procedures, and another suggested worse 1-year but better 3- and 5-year survival rates following the simultaneous approach. The median MINORS score was 10, with incomplete follow-up and outcome reporting accounting primarily for low scores.Conclusion None of the three surgical strategies for synchronous colorectal liver metastases appeared inferior to the others.
    British Journal of Surgery 03/2014; · 4.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: One in ten patients with rectal cancer presents with synchronous colorectal liver metastases. We present an up-to-date review of the different surgical strategies available for rectal cancer patients with synchronous colorectal liver metastases. METHOD: A literature review of MEDLINE, Cochrane and Google scholar was performed. RESULTS: Twenty retrospective studies comparing staged versus simultaneous resections were found. Overall survival was similar for both approaches whilst the length of stay was decreased in simultaneous resections. Only two studies comparing the 'reverse' versus staged or simultaneous resections were found. The studies investigating resection versus non-resection for rectal primaries with unresectable liver metastases were limited. CONCLUSION: Simultaneous resections are a reasonable alternative to staged resections for either advanced rectal cancers with limited liver disease or early rectal cancers with extensive liver disease. Currently, staged resections are favoured over simultaneous resections in patients with locally advanced rectal cancers with extensive liver disease. There are too few studies to determine the safety of reverse resections in the context of locally advanced rectal cancers. A resection of the primary tumour or a non-surgical intervention can be justified in the management of the rectal cancer primary in the presence of unresectable liver metastases.
    Techniques in Coloproctology 09/2012; · 1.54 Impact Factor